CRN Monthly Update for March/April 2015

In this issue:

Highlights

Michael Gould of KP Southern California received a grant from PCORI. The objective is to conduct a pragmatic trial of different surveillance intervals after detection of a lung nodule, and involves several CRN Sites and other institutions. Michael Gould and his co-PIs, Diana Miglioretti and Karen Kelly of UC Davis, and Rebecca Smith-Bindman of UCSF, were brought together through CRN facilitation. Congratulations to the whole research team!

Diana Miglioretti, UC Davis and Group Health, Rebecca Smith-Bindman, UCSF, and Marilyn Kwan, KPNC, are multiple PIs of a recently-funded R01 from the NCI to examine cancer risk associated with medical radiation exposures, focusing primarily on CT use and childhood leukemia risk. This grant, which grew out of a CRN Pilot Project funded under CRN3, involves several CRN Sites, including Group Health, KP Northwest (Sheila Weinmann, Site PI), KPNC, and KPSC (Reina Haque, Site PI). Congratulations to everyone - and once again to Diana and Rebecca!

The CRN congratulates Neetu Chawla, KPNC, who has been accepted into the Mentored Training in Dissemination and Implementation Research in Cancer (MT-DIRC) Program, led by Ross Brownson and colleagues at Washington University, St. Louis, MO. MT-DIRC provides an outstanding opportunity to engage with leaders in dissemiantion and implementation research during a two-year training program. The CRN partners with the MT-DIRC, in which we support participation for a CRN-based scientist in this program. The CRN looks forward to supporting Neetu's participation as we increase the capacity to increase D&I research in the CRN. Congratulations once again to Neetu!

[Return to Top]

New Scholars Program Co-Lead

The CRN is pleased to announce that Jennifer Elston Lafata, Professor at Virginia Commonwealth University and co-leader of the Cancer Prevention and Control Program, Massey Cancer Center, has joined the CRN to co-lead the CRN Scholars Program. Aside from a long-standing interest in mentoring and career development, Jennifer brings familiarity with both the CRN setting - she was at Henry Ford Health System for many years - and an Academic Health Center to the CRN. She came highly recommended by many for this role, from colleagues throughout the CRN, the health services research community, and the NCI.

While the CRN generally, and the Scholars Program specifically, will benefit greatly from Jennifer's leadership, the opportunity to bring her on board resulted from the planned and imminent retiring of Terry Field, Meyers Primary Care Institute, who has been actively involved with the CRN for many years and most recently steered the CRN Scholars Program with colleagues Diana Buist and Sarah McDonald. The CRN will miss Terry's enthusiasm for mentoring young investigators, her outstanding scholarship in breast cancer, aging, epidemiologic methods, and health services research, and her ready smile. However, we also celebrate Terry's transition to the next phase of her life, where she no longer has to think about that next grant application.

[Return to Top]

Opportunity Funds

The Coordinating Center recently sent out the Opportunity Fund Call for ApplicationsExternal Web Site Policy. In an effort to support project development, this solicitation is focused specifically on support of activities in the CRN setting that will result in submission of a competitive R01 or similar application for grant funding. In past years, the CRN has sent out a Pilot and Developmental Projects Call for Applications. The Opportunity Fund mechanism is slightly different in that the scope of activities for any given project and application will be completed in a shorter time frame – on the order of a few months, with a maximum of 12 months, will be no more than $25,000 in direct cost, but preferably smaller, and will clearly define steps for and lay the ground work for submitting an R01 or similar grant.

For more information about the Opportunity Fund, including who can apply, evaluation criteria, and more, please email us.

[Return to Top]

KP TRIO Quarterly Meetings

KP TRIO - Translational Research in Oncology - provides a forum for discussion of initiatives, activities, funding opportunities, etc. of interest to the "trio" of clinicians, operations, and researchers within Kaiser Permanente. Held via webinar, with some people gathering locally, it is typically attended by people from all seven of the KP regions, by clinicians across a variety of cancer-related specialties including Chiefs of Medical Oncology, radiation oncologists, oncology pharmacists, and other providers; people from some of KP's internal quality improvement or other leadership groups; and from researchers affiliated with KP research groups.

Although the focus of KP TRIO has been on issues with a specific focus on Kaiser Permanente interests, many, if not most, discussion items are likely of interest to the CRN community. If you are interested in receiving notifications about upcoming agendas, please contact Heather Clancy.

2015 Meeting Schedule
Meetings are held quarterly on the third Thursday of the month, 8:30-11:00 Pacific
March 19, 2015
June 18, 2015
September 17, 2015
December 17, 2015

[Return to Top]

Recent CRN-Related Publications

Jensen CD, Doubeni CA, Quinn VP, Levin TR, Zauber AG, Schottinger JE, Marks AR, Zhao WK, Lee JK, Ghai NR, Schneider JL, Fireman BH, Quesenberry CP, Corley DA. Adjusting for Patient Demographics Has Minimal Effects on Rates of Adenoma Detection in a Large, Community-based Setting. Clin Gastroenterol Hepatol 2015 Apr;13(4):739-46. [View Abstract]

Haque R, Shi J, Schottinger JE, Ahmed SA, Chung J, Avila C, Lee VS, Cheetham TC, Habel LA, Fletcher SW, Kwan ML. A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care 2015 Apr;53(4):380-5. doi: 10.1097/MLR.0000000000000327. [View Abstract]

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, Ballegooijen Mv, Corley DA, Zauber AG. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol 2015 Mar;25(3):208-213.e1. [View Abstract]

Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer 2015 Mar 12. [Epub ahead of print] [View Abstract]

Keegan TH, Kurian AW, Gali K, Tao L, Lichtensztajn DY, Hershman DL, Habel LA, Caan BJ, Gomez SL. Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System. Am J Public Health 2015 Mar 19:e1-e9. [Epub ahead of print] [View Abstract]

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst 2015 Feb 16;107(4). pii: djv012. Print 2015 Apr. [View Abstract]

Gao H, Aiello Bowles EJ, Carrell D, Buist DS. Using natural language processing to extract mammographic findings. J Biomed Inform 2015 Feb 3. pii: S1532-0464(15)00012-X. [Epub ahead of print] [View Abstract]

Thomas AA, Wallner LP, Quinn VP, Slezak J, Van Den Eeden SK, Chien GW, Jacobsen SJ. Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study. Urology 2015 Feb;85(2):388-92. [View Abstract]

Sakoda LC, Ferrara A, Achacoso NS, Peng T, Ehrlich SF, Quesenberry CP Jr, Habel LA. Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila). 2015 Feb;8(2):174-9. doi: 10.1158/1940-6207.CAPR-14-0291. [View Abstract]

O'Neill SC, Tercyak KP, Baytop C, Hensley Alford S, McBride CM. A new approach to assessing affect and the emotional implications of personal genomic testing for common disease risk. Public Health Genomics 2015;18(2):104-12. [View Abstract]

Hoffmann TJ, Sakoda LC, Shen L, Jorgenson E, Habel LA, Liu J, Kvale MN, Asgari MM, Banda Y, Corley D, Kushi LH, Quesenberry CP Jr, Schaefer C, Van Den Eeden SK, Risch N, Witte JS. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet 2015 Jan 28;11(1):e1004930. eCollection 2015 Jan. [View Abstract]

Feigelson HS, Carroll NM, Weinmann S, Haque R, Yu CL, Butler MG, Waitzfelder B, Wrenn MG, Capra A, McGlynn EA, Habel LA. Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans. Springerplus 2015 Jan 17;4:24. eCollection 2015. [View Abstract]

[Return to Top]

Calls for Abstracts

AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer TherapyExternal Web Site Policy - Abstracts due Monday, April 6, 2015.

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically UnderservedExternal Web Site Policy - Abstracts due Thursday, August 6, 2015.

[Return to Top]

Additional Funding Opportunities

NCI Provocative Questions - Applications Due June 29th

PQ 12 - What methods and approaches induce physicians and health systems to abandon ineffective interventions or discourage adoption of unproven interventions?

Intent: Well-intentioned efforts to speed diffusion of research results into practice may result in the adoption of new treatments and approaches to care before their effectiveness has been documented. Multiple studies have documented the continued use of some medical treatments and approaches to cancer care known to be ineffective. This Provocative Question seeks hypothesis-driven studies that explicitly examine how physicians and/or health systems can be induced to diminish delivery of ineffective or unproven cancer care. Responsive applications may, for example, involve the study of natural experiments, such as changes in reimbursement or institutional policy, or the development and testing of interventions targeted at providers or delivery systems. Studies focused on patient factors or including interventions involving only patients are not responsive to this question.

2015 Training Institute for Dissemination and Implementation Research in Health (TIDIRH)External Web Site Policy

July 26-31, 2015 - Pasadena, CA
Applications now being accepted through April 10, 2015

Kaiser Permanente and the Cancer Research Network, with support from the National Institutes of Health (National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, and the Office of Behavioral and Social Sciences Research) and the U.S. Department of Veterans Affairs is hosting this 5-day training institute to provide participants with a thorough grounding in conducting dissemination and implementation research in health across all areas of health and healthcare.

This training is designed for investigators at any career stage interested in conducting Dissemination and Implementation (D&I) research. To be eligible, participants must NOT have current R18, R01 or R01-equivalent funding as a principal investigator for D&I research or received such funding in the in the past five year(s).

[Return to Top]

Employment Opportunities

Health Scientist, Outcomes Research
National Cancer Institute

The Outcomes Research Branch within the Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences has an exciting opportunity available for a Health Scientist! The candidate who fills this position will facilitate an innovative program of research related to outcomes measurement in cancer care, including quality of life, patient experiences of care, cancer survivorship and care quality.

Candidates must have a Ph.D. or equivalent and demonstrated expertise in one or more of the following: behavioral science, social science, clinical medicine, nursing, psychology or social work, and/or health services research. Interested applicants should submit a letter of interest, CV, and two representative publications to Kate McNeill. Specific questions about the position can be directed to Ashley Wilder Smith, Chief of the Outcomes Research Branch.

More information about this position is available at the HDRP Web site.

Copyright © 2015 The Cancer Research Network, All rights reserved.